RxDoctor Payments DataLook up a doctor →

Mark Abumoussa, MD

Pain Medicine · Hollywood, FLNPI 1740719889

Payments from drug & device makers

$30,211in general payments, 2019–2025

Across 642 payments — averaging $47.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik NRO, Inc.$23K
  • Abbott$2K
  • Scilex Pharmaceuticals Inc.$988
  • Medtronic$550
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$480
  • Protega Pharmaceutials Inc$450
  • plus $2K from 26 others

What the payments were for

  • Speaking & faculty fees$4501%
  • Food & beverage$29,76199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,211 in reported general payments places this provider in the 90th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$465,109
Medicare patients
1,018
Services billed
5,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl1,163$18,077
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen836$12,112
Tramadol Hcl757$6,373
Pregabalin225$4,959
Buprenorphine18$3,791
Fentanyl44$2,652
Lacosamide28$2,436
Morphine Sulfate86$2,280
Acetaminophen-CodeineAcetaminophen With Codeine42$1,359
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$1,174
Gabapentin124$1,105
Hydromorphone Hcl67$894
Cyclobenzaprine Hcl65$861
Duloxetine Hcl16$754
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen35$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$14$6,071104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →